167 related articles for article (PubMed ID: 28529321)
1. Colorectal cancer drugs market.
Cassidy S; Syed BA
Nat Rev Drug Discov; 2017 Aug; 16(8):525-526. PubMed ID: 28529321
[No Abstract] [Full Text] [Related]
2. Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs.
Amir E; Seruga B; Martinez-Lopez J; Kwong R; Pandiella A; Tannock IF; Ocaña A
J Clin Oncol; 2011 Jun; 29(18):2543-9. PubMed ID: 21606435
[TBL] [Abstract][Full Text] [Related]
3. Challenges and opportunities for use of cost-effectiveness analysis.
Yabroff KR; Schrag D
J Natl Cancer Inst; 2009 Sep; 101(17):1161-3. PubMed ID: 19666852
[No Abstract] [Full Text] [Related]
4. The price tag on progress--chemotherapy for colorectal cancer.
Schrag D
N Engl J Med; 2004 Jul; 351(4):317-9. PubMed ID: 15269308
[No Abstract] [Full Text] [Related]
5. Cetuximab in colon cancer.
Martin MJ
N Engl J Med; 2004 Oct; 351(15):1575-6; author reply 1575-6. PubMed ID: 15473023
[No Abstract] [Full Text] [Related]
6. The development of a value based pricing index for new drugs in metastatic colorectal cancer.
Dranitsaris G; Truter I; Lubbe MS
Eur J Cancer; 2011 Jun; 47(9):1299-304. PubMed ID: 21493060
[TBL] [Abstract][Full Text] [Related]
7. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.
Mittmann N; Au HJ; Tu D; O'Callaghan CJ; Isogai PK; Karapetis CS; Zalcberg JR; Evans WK; Moore MJ; Siddiqui J; Findlay B; Colwell B; Simes J; Gibbs P; Links M; Tebbutt NC; Jonker DJ; ;
J Natl Cancer Inst; 2009 Sep; 101(17):1182-92. PubMed ID: 19666851
[TBL] [Abstract][Full Text] [Related]
8. Economics of ramucirumab for metastatic colorectal cancer.
Zeichner SB; Kohn CG; Goldstein DA
Expert Rev Pharmacoecon Outcomes Res; 2016 Dec; 16(6):733-745. PubMed ID: 27828732
[TBL] [Abstract][Full Text] [Related]
9. Cost utility of sequential adjuvant trastuzumab for HER2/Neu-positive breast cancer.
Reed SD; Schulman KA
Value Health; 2009; 12(5):637-40. PubMed ID: 19473336
[No Abstract] [Full Text] [Related]
10. A generalized health economic and outcomes research model for the evaluation of companion diagnostics and targeted therapies.
Lee J; Tollefson E; Daly M; Kielb E
Expert Rev Pharmacoecon Outcomes Res; 2013 Jun; 13(3):361-70. PubMed ID: 23763533
[TBL] [Abstract][Full Text] [Related]
11. Colorectal cancer market.
Smith RE; Renaud RC; Hoffman E
Nat Rev Drug Discov; 2004 Jun; 3(6):471-2. PubMed ID: 15214331
[No Abstract] [Full Text] [Related]
12. No rational theory for drug pricing.
Cox MC; Figg WD; Thurman PW
J Clin Oncol; 2004 Mar; 22(5):962-3. PubMed ID: 14990657
[No Abstract] [Full Text] [Related]
13. [Utilization of antineoplastic agents in Sweden and Europe].
Wilking N; Jönsson B; Björn W
Lakartidningen; 2010 Apr 21-27; 107(16):1075-80. PubMed ID: 20476705
[No Abstract] [Full Text] [Related]
14. Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?
Goldstein DA; El-Rayes BF
Oncologist; 2015 Sep; 20(9):981-2. PubMed ID: 26265225
[TBL] [Abstract][Full Text] [Related]
15. Genentech caps cost of cancer drug for some patients.
Pollack A
N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
[No Abstract] [Full Text] [Related]
16. Cost-minimization analysis of the treatment of patients with metastatic colorectal cancer in Greece.
Fragoulakis V; Papagiannopoulou V; Kourlaba G; Maniadakis N; Fountzilas G
Clin Ther; 2012 Oct; 34(10):2132-42. PubMed ID: 23063374
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of bevacizumab combined with chemotherapy for the treatment of metastatic colorectal cancer in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Clin Ther; 2007 Oct; 29(10):2256-67. PubMed ID: 18042483
[TBL] [Abstract][Full Text] [Related]
18. [Costs, disease management and DRG].
Barni S; Mandalà M; Gambera M
Tumori; 2001; 87(1 Suppl 1):S59. PubMed ID: 11300029
[No Abstract] [Full Text] [Related]
19. Longitudinal trends in use and costs of targeted therapies for common cancers in Taiwan: a retrospective observational study.
Hsu JC; Lu CY
BMJ Open; 2016 Jun; 6(6):e011322. PubMed ID: 27266775
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal trends in use of targeted therapies for treatment of malignant neoplasms of the eye: a population-based study in Taiwan.
Hsu JC; Gonzalez-Gonzalez LA; Lu VH; Lu CY
BMJ Open; 2016 May; 6(5):e010706. PubMed ID: 27235298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
